Multiple Sclerosis Trial Exhibits Positive Results of Stem Cell Therapy.

A five year phase II clinical trial has shown initial success in treating multiple sclerosis.

In a recent update of an ongoing five year clinical trial conducted by the Chicago Blood Cancer Institute, patients with relapsing-remitting multiple sclerosis have experienced suppression of disease-related inflammation as a result of hematopoietic stem cell transplantations.  The stem cells have the ability to regulate the autoimmune attack on the central nervous system, and have provided 82.8% of the patients with two years thus far of event-free disease remission. Continue reading

Stem Cell Treatment for Heart Damage Progresses to Phase 2 Clinical Trials

The progression of stem cell treatments is the only way to help the heart regenerate its own muscle.

Research teams from Cedars-Sinai Heart Institute and the Minneapolis Heart Institute with funding from CIRM [California Institute for Regenerative Medicine] are moving to Phase 2 Clinical Trials for a treatment that utilizes cardiac stem cells to repair severe heart damage.  The treatment development was led by Eduardo Marbán, a director at the Cedars-Sinai Heart Institute and founder of Capricor.  This groundbreaking treatment involves the injection of stem cells into the coronary artery, which then migrate to the heart and promote the regrowth of healthy heart muscle. Continue reading